Alumis是一家生物制药公司,尽管股价低,仍保持“买入”评级,重点是开发TYK2抑制剂。 Alumis, a biopharmaceutical firm, keeps "buy" rating despite low share price, focusing on developing TYK2 inhibitors.

Alumis是一家开发TYK2抑制剂的生物制药公司, 一直维持分析师的“购买”评级, Alumis, a biopharmaceutical company developing TYK2 inhibitors, has maintained a "buy" rating from analysts with a consensus target price of $26.00. 该公司的股份开放额为3.57美元,52周的营业额为3.52至13.53美元。 The company's shares opened at $3.57, with a 52-week range of $3.52 to $13.53. Alumis目前正在研制两种TYK2抑制剂,即ESK-001和A-005,旨在进行有针对性的免疫学治疗。 Alumis is currently developing two TYK2 inhibitors, ESK-001 and A-005, aiming for targeted therapies in immunology.